40665-68-7Relevant articles and documents
He fluorine front row element intermediate preparation method (by machine translation)
-
Paragraph 0034; 0035; 0036, (2018/05/16)
The invention discloses he fluorine front row element intermediate, i.e. formula 5 compound preparation method, including the use of biphenyl formyl protected Corey lactone as raw materials, through oxidation, HWE connected side chain, fluorinated, hydrolysis of deprotection step. Preparation method of this invention has the operability is strong, stable process, intermediates for the preparation of white powder, good stability. (by machine translation)
Preparation method of beta-carboxyl phosphate
-
Paragraph 0086; 0089; 0090, (2017/09/01)
The invention provides a preparation method of beta-carboxyl phosphate. The preparation method comprises the following steps: carrying out regional selective ring-opening reaction on an epoxy compound and trialkyl phosphite to generate beta-carboxyl phosphate intermediate; and then oxidizing the beta-carboxyl phosphate intermediate to obtain the beta-carboxyl phosphate. The method is gentle in reaction condition and simple and convenient to operate without protection of an anhydrous solvent and oxygen, and is suitable for large-scale production. The beta-carboxyl phosphate synthesized by the preparation method can be used as an important intermediate synthesized by various misoprostols, such as travoprost, bimatoprost and tafluprost.
Synthesis of (±) travoprost and its analogs
Mudduluru, Harikrishna,Hindupur, Rama M.,Dubey, Pramod K.,Madhavaram, Shankar,Tatini, Lakshmikumar,Subbaraju, Gottumukkala V.
experimental part, p. 234 - 241 (2012/04/18)
A new synthetic approach for the antiglaucoma agent, travoprost (1) has been developed in four steps from key intermediate (2). Key transformations include Horner-Wadsworth-Emmons reaction and separation of diastereomers to obtain (±) travoprost (1) and its analogs.
PROSTANOIDS. XXX. SYNTHESIS OF THE ANALOGS OF 11-DEOXYPROSTA-GLANDINS E AND F
Tolstikov, G. A.,Miftakhov, M. S.,Adler, M. E.,Platonov, V. E.,Sagitdinova, Kh. F.,Khalilov, L. M.
, p. 100 - 107 (2007/10/02)
A practical approach to 11-deoxyprostaglandins is developed on the basis of the chemo- and stereoselective reduction of the readily obtainable methyl 9,15-diketo-16-aryloxyprostenoates.
2,5,6,7-tetranor-4,8-inter-m-phenylene PGI2 derivatives
-
, (2008/06/13)
Disclosed herein are novel prostaglandin I2 (PGI2) derivatives exhibiting excellent in vivo duration and activities, said derivatives being represented by the general formula: STR1 wherein R1, X, R2 and R3 are as defined herein.
9-Substituted carbacyclin analogs
-
, (2008/06/13)
Novel compounds of the following formula: STR1
9-Substituted carbacyclin analogs
-
, (2008/06/13)
Novel compounds of the following general formula: STR1
9-Substituted carbacyclin analogs
-
, (2008/06/13)
Novel compounds of the following general formula: STR1
Method of inducing luteolysis using 16-aryloxy-17,18,19,20-tetranor-prostanoic acid derivatives
-
, (2008/06/13)
The disclosure relates to novel 17,18,19,20-tetranor-prostanoic acid derivatives having prostaglandin-type properties, to a method for their manufacture, and also to pharmaceutical or veterinary compositions containing said novel derivatives and a method of inducing luteolysis in an animal host by use of said novel derivatives.
N-(Methanesulfonyl)-16-phenoxyprostaglandincarboxamides: Tissue-Selective, Uterine Stimulants
Schaaf, Thomas K.,Bindra, Jasjit S.,Eggler, James F.,Plattner, Jacob J.,Nelson, A. James,et al.
, p. 1353 - 1359 (2007/10/02)
In an effort to develop tissue-selective prostaglandin analogues resistant to the metabolic inactivating pathways of the natural materials, hybrid compounds modified both at C-1 with a sulfonimide moiety and in the n-amylcarbinol side chain with substituted phenoxy groups were synthesized and evaluated in a variety of in vitro and in vivo models.Several of these analogues exhibited potent, tissue-selective, uterine stimulant activity, a finding subsequently confirmed in clinical studies with one member of this series, N-(methanesulfonyl)-16-phenoxy-ω-tetranor-PGE2-carboxamide (CP-34089/ZK-57671, sulprostone).